Mind Medicine (MindMed) Inc. MNMD stock fell 0.3% in premarket trades after the psychedelic medicine maker issued its letter to shareholders urging them to vote for its board of directors at its June 15 shareholder meeting rather than rival nominees from meme stock trader Jake Freeman. MindMed said its nominees “possess essential pharmaceutical industry, capital allocation and corporate governance experience” at a pivotal moment for the company. MindMed expects to receive data on key Phase 2 trials in MM-120 and initiate its first sponsored clinical trial of MM-402. MM-110 and MM-120 are forms of LSD with the former currently…
